Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
8.33
+0.03 (0.36%)
Aug 14, 2025, 11:40 AM - Market open
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $-249.00K in the twelve months ending June 30, 2025, down -100.08% year-over-year. In the year 2024, Amylyx Pharmaceuticals had annual revenue of $87.37M, down -77.06%.
Revenue (ttm)
$-249.00K
Revenue Growth
-100.08%
P/S Ratio
-2,972.25
Revenue / Employee
n/a
Employees
123
Market Cap
742.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AMLX News
- 6 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results - Business Wire
- 14 days ago - Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 23 days ago - Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential - Seeking Alpha
- 4 weeks ago - Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery - Benzinga
- 4 weeks ago - Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - Business Wire
- 5 weeks ago - Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025 - Business Wire
- 7 weeks ago - Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market - Benzinga